iShares U.S. Home Construction ETF (ITB)
- Previous Close
118.10 - Open
119.12 - Bid 113.00 x 800
- Ask 121.52 x 1400
- Day's Range
117.97 - 120.13 - 52 Week Range
85.67 - 129.89 - Volume
2,511,667 - Avg. Volume
1,645,370 - Net Assets 3.36B
- NAV 118.99
- PE Ratio (TTM) 13.11
- Yield 0.39%
- YTD Daily Total Return 18.35%
- Beta (5Y Monthly) 1.56
- Expense Ratio (net) 0.39%
The index measures the performance of the home construction sector of the U.S. equity market, as defined by the index provider. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. It is non-diversified.
iShares
Fund Family
Consumer Cyclical
Fund Category
3.36B
Net Assets
2006-05-01
Inception Date
Performance Overview: ITB
View MoreTrailing returns as of 11/7/2024. Category is Consumer Cyclical.
People Also Watch
Holdings: ITB
View MoreTop 10 Holdings (65.72% of Total Assets)
Sector Weightings
Recent News: ITB
View MoreResearch Reports: ITB
View MoreBiopharma Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetBiopharma Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetBUY as company raises earnings guidance
Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in multiple sclerosis drugs and launched the first approved treatments for spinal muscular atrophy and Alzheimer's disease. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,570 people, and is a component of the S&P 500.
RatingPrice TargetBiogen Earnings: Full-Year Guidance Raised; Early Leqembi Sales Encouraging but Uncertainty Remains
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice Target